Technical Analysis for CVAC - CureVac N.V.

Grade Last Price % Change Price Change
grade D 52.09 -1.53% -0.81
CVAC closed down 1.53 percent on Friday, September 18, 2020, on 22 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical CVAC trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -1.53%
Gapped Down Weakness -1.53%
Oversold Stochastic Weakness -1.53%
Narrow Range Bar Range Contraction -3.50%
NR7 Range Contraction -3.50%
NR7-2 Range Contraction -3.50%
Up 3 Days in a Row Strength -3.50%
Older End-of-Day Gignals for CVAC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 23 hours ago
60 Minute Opening Range Breakdown about 23 hours ago
Rose Above Previous Day's High 1 day ago
Down 1% 1 day ago
Down 3% 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Biopharmaceutical Solid Tumors Health Care Vaccination Pharmaceutical Companies Rabies Arcturus Therapeutics Boehringer Ingelheim

Is CVAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 85.0
52 Week Low 36.15
Average Volume 2,159,897
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 57.29
10-Day Moving Average 54.90
Average True Range 5.78
ADX 0.0
+DI 22.65
-DI 18.61
Chandelier Exit (Long, 3 ATRs ) 52.39
Chandelier Exit (Short, 3 ATRs ) 68.60
Upper Bollinger Band 65.46
Lower Bollinger Band 49.11
Percent B (%b) 0.18
BandWidth 28.54
MACD Line -3.64
MACD Signal Line -2.66
MACD Histogram -0.9814
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.52
Resistance 3 (R3) 54.65 53.96 54.12
Resistance 2 (R2) 53.96 53.34 53.90 53.98
Resistance 1 (R1) 53.03 52.96 52.69 52.90 53.84
Pivot Point 52.34 52.34 52.17 52.28 52.34
Support 1 (S1) 51.41 51.72 51.07 51.28 50.34
Support 2 (S2) 50.72 51.34 50.66 50.20
Support 3 (S3) 49.79 50.72 50.07
Support 4 (S4) 49.66